- Home
- BACK vs SLRX Comparison
BACK vs SLRX Comparison
Compare BACK & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BACK
- SLRX
- Stock Information
- Founded
- BACK 2000
- SLRX N/A
- Country
- BACK United States
- SLRX United States
- Employees
- BACK N/A
- SLRX N/A
- Industry
- BACK Medical Specialities
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BACK Health Care
- SLRX Health Care
- Exchange
- BACK Nasdaq
- SLRX Nasdaq
- Market Cap
- BACK 2.2M
- SLRX 2.0M
- IPO Year
- BACK 2019
- SLRX N/A
- Fundamental
- Price
- BACK $1.10
- SLRX $1.22
- Analyst Decision
- BACK
- SLRX
- Analyst Count
- BACK 0
- SLRX 0
- Target Price
- BACK N/A
- SLRX N/A
- AVG Volume (30 Days)
- BACK 23.2K
- SLRX 30.5K
- Earning Date
- BACK 12-31-2024
- SLRX 11-14-2024
- Dividend Yield
- BACK N/A
- SLRX N/A
- EPS Growth
- BACK N/A
- SLRX N/A
- EPS
- BACK N/A
- SLRX N/A
- Revenue
- BACK N/A
- SLRX N/A
- Revenue This Year
- BACK N/A
- SLRX N/A
- Revenue Next Year
- BACK N/A
- SLRX N/A
- P/E Ratio
- BACK N/A
- SLRX N/A
- Revenue Growth
- BACK N/A
- SLRX N/A
- 52 Week Low
- BACK $0.98
- SLRX $1.22
- 52 Week High
- BACK $7.75
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- BACK 45.18
- SLRX 35.59
- Support Level
- BACK $1.06
- SLRX $1.35
- Resistance Level
- BACK $1.21
- SLRX $1.67
- Average True Range (ATR)
- BACK 0.10
- SLRX 0.12
- MACD
- BACK 0.01
- SLRX -0.02
- Stochastic Oscillator
- BACK 29.17
- SLRX -15.38
About BACK IMAC Holdings Inc.
IMAC Holdings Inc is a provider and manager of value-based, conservative medical care combining life science advancements with traditional medical care for movement-restricting diseases and conditions in IMAC Regeneration Centers and BackSpace clinics. Its Innovative Medical Advancements and Care (IMAC) Regeneration Centers combine medical and physical procedures to improve patient experiences and outcomes and reduce healthcare costs as compared to other available treatment options.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.